SCHEMBL9906119

SCHEMBL9906119

N[C@@H](c1cccc2ccccc12)[C@@H](N)c1cccc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
CYP1A2 P05177 3/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
TSHR P16473 2/20 0.48
HSD17B10 Q99714 2/20 0.48
CYP3A4 P08684 1/20 0.48
HPGD P15428 1/20 0.48
KEAP1 Q14145 1/20 0.48
CYP2A6 P11509 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
AOC3 Q16853 1/20 0.44
ADRA2A P08913 3/20 0.42
ADRA2B P18089 3/20 0.42
ADRA2C P18825 3/20 0.42
ADRA1A P35348 3/20 0.42
ADRA1D P25100 2/20 0.42
ADRA1B P35368 2/20 0.42
HPRT1 P00492 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24017144 1.00 ALDH1A1 (0.60) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL29887508 1.00 ALDH1A1 (0.60) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL2067587 1.00 ALDH1A1 (0.60) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
Hydrochloric Acid SCHEMBL30098262 0.98 ALDH1A1 (0.58) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
Hydrochloric Acid SCHEMBL14119362 0.98 ALDH1A1 (0.58) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
Hydrochloric Acid SCHEMBL19951713 0.98 ALDH1A1 (0.58) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL12101209 0.87 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL31360342 0.87 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL25155348 0.87 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR
SCHEMBL11817158 0.87 ALDH1A1 (0.52) ALDH1A1CYP1A2CYP2C9CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022175693-A1 PROCESS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2022-08-25 WO disclosed
US-10392353-B2 Processes for making substituted quinazoline compounds using hydrogen bonding catalysts MERCK SHARP & DOHME CORP. (US) 2019-08-27 US disclosed
US-9701684-B2 Chiral fluorinating reagents OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2017-07-11 US disclosed
WO-2017091453-A1 NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS MERCK SHARP & DOHME CORP. (US) 2017-06-01 WO disclosed
US-20150284401-A1 CHIRAL FLUORINATING REAGENTS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2015-10-08 US disclosed
EP-2914582-A2 CHIRAL FLUORINATING REAGENTS Isis Innovation Limited (GB) 2015-09-09 EP disclosed
WO-2014068341-A2 CHIRAL FLUORINATING REAGENTS ISIS INNOVATION LIMITED (GB) 2014-05-08 WO disclosed
US-8198488-B2 Hydrogenation of esters with Ru/bidentate ligands complexes FIRMENICH SA (CH) 2012-06-12 US disclosed
US-8198488-B2 Hydrogenation of esters with Ru/bidentate ligands complexes FIRMENICH SA (CH) 2012-06-12 US disclosed
US-20100286452-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2010-11-11 US disclosed
US-20100286452-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2010-11-11 US disclosed
EP-2089345-B1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH & CIE (CH) 2010-02-24 EP disclosed
WO-2008065588-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286452-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES ADH1A, ADH5, ADH1C ALDH1A1 783/4885CYP1A2 522/4885CYP2C9 1019/4885
US-20150284401-A1 CHIRAL FLUORINATING REAGENTS TIAM1, AFF2, AFF1 ALDH1A1 800/4885CYP1A2 218/4885CYP2C9 820/4885
US-10392353-B2 Processes for making substituted quinazoline compounds using hydrogen bonding catalysts NQO1, NDUFS7, NDUFS2 ALDH1A1 1056/4885CYP1A2 64/4885CYP2C9 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.